Annexin-A1 short peptide alleviates septic myocardial injury by upregulating SIRT3 and inhibiting myocardial cell apoptosis

• Song Qin ^[2] ; Yingcong Ren ^[2] ; Banghai Feng ^[3] ; Xiaoqin Wang ^[4] ; Junya Liu ^[2] ; Jie Zheng ^[1] ; Kang Li ^[2] ; Hong Mei ^[2] ; Qiuyu Dai ^[1] ; Hong Yu ^[2] ; Xiaoyun Fu ^[2]
  1. [1] Zunyi Medical University

     Zunyi Medical University

     China

     
  2. [2] Affiliated Hospital of Zunyi Medical University, PR China
  3. [3] Zunyi Hospital of Traditional Chinese Medicine, PR China
  4. [4] The Second Affiliated Hospital of Zunyi Medical University, PR China

  Mostrar afiliaciones +
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 39, Nº. 7, 2024, págs. 947-957
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Septic myocardial injury is a common complication of severe sepsis, which occurs in about 50% of cases. Patients with this disease may experience varying degrees of myocardial damage. Annexin-A1 short peptide (ANXA1sp), with a molecular structure of Ac-Gln-Ala-Tyr, has been reported to exert an organ protective effect in the perioperative period by modulating sirtuin-3 (SIRT3). Whether it possesses protective activity against sepsis-induced cardiomyopathy is worthy of study. This study aimed to investigate whether ANXA1sp exerts its anti-apoptotic effect in septic myocardial injury in vitro and in vivo via regulating SIRT3. In this study, we established in vivo and in vivo models of septic myocardial injury based on C57BL/6 mice and primary cardiomyocytes by lipopolysaccharide (LPS) induction. Results showed that ANXA1sp pretreatment enhanced the seven-day survival rate, improved left ventricular ejection fraction (EF), left ventricular fractional shortening (FS), and cardiac output (CO), and reduced the levels of creatine kinase-MB (CK-MB), cardiac troponin I (cTnI), and lactate dehydrogenase (LDH). Western blotting results revealed that ANXA1sp significantly increased the expression of SIRT3, Bcl-2, and downregulated Bax expression.

    TUNEL staining and flow cytometry results showed that ANXA1sp could attenuate the apoptosis rate of cardiomyocytes, whereas this anti-apoptotic effect was significantly attenuated after SIRT3 knockout. To sum up, ANXA1sp can alleviate LPS-induced myocardial injury by reducing myocardial apoptosis via SIRT3 upregulation.